Major Autohemotherapy (MAH)

Within CMN Hospital’s 28-Day Inpatient Advanced Cancer Treatment Program

Major Autohemotherapy (MAH) is an ozone-based procedure integrated into CMN Hospital’s 28-day inpatient Advanced Cancer Treatment Program as part of a structured clinical protocol within the overall treatment framework.

MAH involves drawing a small amount of blood, combining it with medical-grade ozone in a controlled sterile system, and reinfusing it intravenously as part of the inpatient treatment process.

Clinical Structure of the Program

Oxygen-Based Therapies Within Coordinated Inpatient Care

Within the 28-day inpatient program, MAH is one of several oxygen-based therapies coordinated as part of an integrated treatment schedule.

Treatment planning is based on ongoing evaluation, laboratory findings, diagnosis, and patient response throughout the program.

Treatment Philosophy

Patient Response, Balance, and Physician-Directed Adjustments

The program is structured around physiological response rather than intensity or repetition of any single therapy.

Each component is integrated into a coordinated system where therapies are balanced and adjusted according to how the patient responds over time.

Role Within the Treatment Program

Comprehensive Protocol and Daily Care Environment

MAH is included as part of a comprehensive inpatient protocol alongside other oxygen-based therapies.

It is scheduled within the overall treatment structure as part of a coordinated daily care environment.